Iron Overload clinical trials
The registry lists 156 studies for Iron Overload across more than 10 countries. 6 are recruiting or about to start. 66 of them are mainly about Iron Overload (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 2 narrower conditions too, such as Hemochromatosis: 198 studies, 9 open.
Get an email when these change. Save the Iron Overload studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Novartis Pharmaceuticals (37) · Rennes University Hospital (9) · ApoPharma (7) · Shire (5) · HaEmek Medical Center, Israel (5) · University of Wisconsin, Madison (4) · St. Jude Children's Research Hospital (3) · Assiut University (3)
What is being tested here
Drugs under test in Iron Overload studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Deferasirox | 1 | 5 | 34 |
| Deferiprone | 1 | 2 | 11 |
| Deferoxamine | 1 | 1 | 6 |
| Deferitazole | 0 | 0 | 4 |
| SP-420 | 0 | 0 | 3 |
| CN128 | 0 | 0 | 2 |
| Ferrous sulfate | 0 | 1 | 2 |
| Amlodipine | 0 | 1 | 2 |
| VIT-2763 | 0 | 0 | 1 |
| Omega-3 fatty acid | 0 | 1 | 1 |
Drug classes tested here Iron chelators 1 open · Calcium channel blockers 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 5
- Dec 2026Treatment of Hemochromatosis · National Institutes of Health Clinical Center (CC)
- Jan 2027Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption · Cornell University
- Jun 2027Early Screening and Treatment of Heart Complication in Sickle Cell Disease · Inova Health Care Services
- Aug 2027Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation. · Assistance Publique - Hôpitaux de Paris
- Oct 2027Native T1 Mapping and ECV in Chronic Hemolytic Anemia · Assiut University
Who these studies take
Of the 4 Iron Overload studies recruiting now, 3 (75%) set no upper age limit and 1 (25%) stop at 75 or younger. 1 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (25%) | 1 (25%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 4 (100%) | 4 (100%) |
| 50 | 4 (100%) | 4 (100%) |
| 65 | 4 (100%) | 4 (100%) |
| 75 | 3 (75%) | 3 (75%) |
| 85 | 3 (75%) | 3 (75%) |
Across all 156 studies, recruiting or not: 33% stop at 75 or younger and 28% at 65; 55% take children; 1% are for women only and 2% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Iron Overload studies take
Of 13 observational studies under Iron Overload, half reached primary completion within 43 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Observational | 43 mo27–71 · 13 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
- Native T1 Mapping and ECV in Chronic Hemolytic AnemiaOct 20, 2026NCT07882303
Studies
Recruiting first, then most recently updated. Showing 50 of 156. Browse all 156 → or search them.
- Native T1 Mapping and ECV in Chronic Hemolytic AnemiaNot yet recruitingNCT07882303
- Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseRecruitingNCT07023666Phase 21 country
- Neurodegenerative Diseases Progression Markers (MARKERS-NDD)RecruitingNCT065967461 country
- Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.RecruitingNCT070281121 country
- Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece.Not yet recruitingNCT07352878
- "Iron Overload and Endocrinological Diseases"RecruitingNCT061370791 country
- Fully Automated High-Throughput Quantitative MRI of the LiverCompletedNCT052944711 country
- Treatment of HemochromatosisActive, not recruitingNCT00007150Phase 21 country
- Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron AbsorptionActive, not recruitingNCT061466081 country
- Ethnic Differences in Iron Absorption (FeGenes)Active, not recruitingNCT041985451 country
- Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary HemochromatosisActive, not recruitingNCT07332091Phase 218 countries
- Apotransferrin in AtransferrinemiaActive, not recruitingNCT01797055Phase 23 countries
- Evaluate the Efficacy and Safety of Irochel for the Management of Iron Overload in Thalassemia Patients in Comparison With DeferoxamineCompletedNCT07782931Phase 31 country
- Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary StudyCompletedNCT015563601 country
- Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesCompletedNCT02880033Not applicable1 country
- Iron Accumulation in Erythrocytes in PatientsCompletedNCT074865311 country
- Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating TherapyCompletedNCT041716351 country
- Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) PatientsCompletedNCT02164253Phase 21 country
- Elastography vs Iron Regulators in the Diagnosis of Hepatic Fibrosis- Iron Overload in Children With Beta- ThalassemiaCompletedNCT071539261 country
- Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron ContentCompletedNCT020255431 country
- Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy AdultsCompletedNCT06726863Phase 11 country
- Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCTCompletedNCT044232371 country
- Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded PatientsCompletedNCT05355766Phase 21 country
- Inhibitory Effect of a Polyphenol Supplement on Dietary Iron Absorption in Adults with ThalassemiaCompletedNCT05326503Not applicable1 country
- Safety of SP-420 in the Treatment of Transfusional Iron OverloadTerminatedNCT04741542Phase 11 country
- Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)TerminatedNCT03203850Phase 27 countries
- Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron OverloadCompletedNCT02435212Phase 217 countries
- Association Between Iron Reserves and Perioperative Neurocognitive DisordersCompletedNCT06502912
- Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron OverloadCompletedNCT06468423Not applicable1 country
- Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational MaterialsCompletedNCT062152871 country
- MRI QSM Imaging for Iron OverloadCompletedNCT046317181 country
- Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic SyndromeWithdrawnNCT01892644Phase 21 country
- Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young ChildrenCompletedNCT03591575Phase 42 countries
- Natural History Study of FDXR Mutation-related MitochondriopathyCompletedNCT045809791 country
- Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other AnemiasTerminatedNCT02443545Phase 45 countries
- Long-term Clinical Study of CN128 in Thalassemia PatientsCompletedNCT04614779Phase 21 country
- Changes in Pituitary Iron and Volume With DeferasiroxCompletedNCT013766221 country
- Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance ImagingCompletedNCT00401336Not applicable2 countries
- Evaluation of Body Iron Stores in Overweight Healthy VolunteersCompletedNCT02304874Not applicable1 country
- Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only in Patients With Dysmetabolic LiversiderosisCompletedNCT01045525Phase 31 country
- Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)Status unknownNCT00907283Phase 21 country
- Study to Assess Iron Chelation Therapy in Patients With Chronic Iron OverloadCompletedNCT054404871 country
- Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl HydrazoneCompletedNCT00000588Phase 2
- The Iron Content of Ferritin in Serum and Urine of Children With High Serum Ferritin LevelsTerminatedNCT037779041 country
- Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00110266Phase 22 countries
- Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron OverloadCompletedNCT00901199Phase 21 country
- Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other AnemiasTerminatedNCT02041299Phase 48 countries
- Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron OverloadCompletedNCT01254227Phase 28 countries
- Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to FoodCompletedNCT00845871Phase 41 country
- Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron OverloadCompletedNCT03802916Phase 24 countries